NASDAQ:ACRS

Aclaris Therapeutics Stock Forecast, Price & News

$28.96
-0.13 (-0.45 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.60
Now: $28.96
$29.64
50-Day Range
$20.67
MA: $23.97
$29.60
52-Week Range
$1.02
Now: $28.96
$30.38
Volume416,129 shs
Average Volume2.81 million shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933
Employees57
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.23 million
Book Value$1.69 per share

Profitability

Net Income$-161,350,000.00
Net Margins-941.07%

Miscellaneous

Market Cap$1.50 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $25.20
April 1, 2021 |  americanbankingnews.com
Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 5.6%
March 25, 2021 |  americanbankingnews.com
Gaining Ground After A Tough Couple Of Weeks
January 25, 2021 |  finance.yahoo.com
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.81 out of 5 stars

Medical Sector

1185th out of 2,015 stocks

Pharmaceutical Preparations Industry

529th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$28.96
-0.13 (-0.45 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

What stocks does MarketBeat like better than Aclaris Therapeutics?

Wall Street analysts have given Aclaris Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aclaris Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 644,000 shares, a decrease of 15.2% from the February 28th total of 759,000 shares. Based on an average trading volume of 2,870,000 shares, the short-interest ratio is currently 0.2 days. Approximately 1.8% of the shares of the company are sold short.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its earnings results on Wednesday, February, 24th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 104.00% and a negative net margin of 941.07%.
View Aclaris Therapeutics' earnings history
.

How has Aclaris Therapeutics' stock been impacted by COVID-19?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACRS stock has increased by 2,632.1% and is now trading at $28.96.
View which stocks have been most impacted by COVID-19
.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 51, Pay $715.5k)
  • Mr. Frank Ruffo, Co-Founder, CFO & Treasurer (Age 55, Pay $510.89k)
  • Dr. David N. Gordon, Chief Medical Officer (Age 52, Pay $529.07k)
  • Ms. Kamil Ali-Jackson Esq., J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 62)
  • Dr. Joseph Monahan, Chief Scientific Officer
  • Dr. Michael Steven Tung M.D., Sr. VP of Corp. Strategy/Investor Relations (Age 47)
  • Ms. Sheila Kennedy, VP of Marketing
  • Mr. Kevin Scott, VP of Sales
  • Mr. Jeffrey Wayne, Interim Head of Commercial
  • Mr. Gary DeCrescenzo, Sr. VP of Pharmaceutical R&D

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $28.96.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $1.50 billion and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 57 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.